Cequent Nabs Additional $3M in Series A; Novartis Takes Option to IBD Program

The company said it kept its Series A financing round open at the request of other investors and now has pulled in an additional $3 million from Novartis Option Fund. In conjunction with the financing, Cequent has also signed an option to license its nascent inflammatory bowel disease program to Novartis in exchange for cash upfront.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.